IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rennermalm, A.
Right arrow Articles by Flock, J.-I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rennermalm, A.
Right arrow Articles by Flock, J.-I.

 Previous Article  |  Next Article 

Infection and Immunity, May 2004, p. 3081-3083, Vol. 72, No. 5
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.5.3081-3083.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

The Fibrinogen Binding Protein of Staphylococcus epidermidis Is a Target for Opsonic Antibodies

Anna Rennermalm,1 Martin Nilsson,2 and Jan-Ingmar Flock1*

Department of Laboratory Medicine, Division of Clinical Bacteriology, Karolinska Institutet, Stockholm,1 Department of Microbiology, Swedish University of Agricultural Sciences, Uppsala, Sweden2

Received 19 December 2003/ Returned for modification 22 January 2004/ Accepted 5 February 2004

Antibodies against the fibrinogen binding protein (Fbe) of Staphylococcus epidermidis significantly increased macrophage phagocytosis. Antibodies against autolysin E were opsonic but to a lesser extent. Antibodies against a novel, putatively surface-located antigen were unable to enhance phagocytosis. The severity of systemic infection of mice with S. epidermidis was reduced if the bacteria were preopsonized with anti-Fbe prior to administration. Fbe is thus a strong candidate for protein vaccination against S. epidermidis infection, and antibodies against Fbe can be used to prevent or treat infections caused by S. epidermidis.


* Corresponding author. Mailing address: Karolinska Institutet, Department of Laboratory Medicine, Division of Clinical Bacteriology, Huddinge University Hospital, F82, S-141 86 Stockholm, Sweden. Phone: 46 8 5858 1169. Fax: 46 8 711 3918. E-mail: jan-ingmar.flock{at}labmed.ki.se.

Editor: F. C. Fang


Infection and Immunity, May 2004, p. 3081-3083, Vol. 72, No. 5
0019-9567/04/$08.00+0     DOI: 10.1128/IAI.72.5.3081-3083.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2004 by the American Society for Microbiology. All rights reserved.